The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on July 7, 2025

Nudj Health Appoints Dr. Padmaja Patel as Chief Medical Officer to Advance Lifestyle Medicine Services

Nudj Health Appoints Dr. Padmaja Patel as Chief Medical Officer to Advance Lifestyle Medicine Services

PASADENA, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Nudj Health, the leading AI-powered lifestyle medicine services company, is proud to announce the appointment of Dr. Padmaja Patel as Chief Medical Officer of Lifestyle Medicine Services. In this role, Dr …

Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development 

Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development 

MENLO PARK, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Synfini, Inc., a trailblazer in AI-driven chemistry automation, today announced a $8.9 million expansion of its round, led by JSL Health Capital and supported by a strong syndicate of early-stage …

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data …

Ophthalmology Drugs Market to Reach $26.28 Billion by 2030—Vision Care Becomes a Strategic Growth Pillar | MarketsandMarkets™.

Ophthalmology Drugs Market to Reach $26.28 Billion by 2030—Vision Care Becomes a Strategic Growth Pillar | MarketsandMarkets™.

Delray Beach, FL, July 07, 2025 (GLOBE NEWSWIRE) -- What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of …

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has …

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658 Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United …

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 ( …

Medical Supplierz Expands Global Access to Leading Medical Manufacturers

Medical Supplierz Expands Global Access to Leading Medical Manufacturers

KUWAIT, KUWAIT, July 7, 2025 /⁨EINPresswire.com⁩/ -- Medical Supplierz, a digital B2B procurement platform, has launched new initiatives to strengthen global connectivity between verified healthcare buyers and trusted medical manufacturers. The platform …

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

    TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as …

Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire’s management team will host a …

Collegium Announces $150 Million Share Repurchase Program

Collegium Announces $150 Million Share Repurchase Program

STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board …

JenaValve's Trilogy™ THV System Procedures Live Broadcast at New York Valves 2025

JenaValve's Trilogy™ THV System Procedures Live Broadcast at New York Valves 2025

IRVINE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the New York Valves 2025 conference, with two live case …

Novel Digital Test Provides Revolutionary Tool to Assess Brain Chemistry

Novel Digital Test Provides Revolutionary Tool to Assess Brain Chemistry

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- For the first time, a study shows a digital assessment can provide a scientific measure of acetylcholine – a key brain chemical whose decline signals the progression of cognitive impairment and Alzheimer’s …

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform Accelerating the creation of innovation by combining Gero's …

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for …

Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France

Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France

FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it …

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed …

Extendicare Announces Timing of 2025 Second Quarter Results and Conference Call

Extendicare Announces Timing of 2025 Second Quarter Results and Conference Call

MARKHAM, Ontario, July 07, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. …

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service